Walleye Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Walleye Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$947K	Sell	50,800 -3,800	-7%	-$62.9K	﹤0.01%	2125
2025 Q4	$720K	Buy	54,600 +43,000	+371%	+$507K	﹤0.01%	2685
2025 Q3	$83.2K	Buy	+11,600	New	+$605K	﹤0.01%	3796
2025 Q1	–	Sell	-800	Closed	-$43.3K	–	4780
2024 Q4	$43.3K	Sell	800 -2,200	-73%	-$112K	﹤0.01%	4388
2024 Q3	$151K	Buy	+3,000	New	+$141K	﹤0.01%	4183
2024 Q2	–	Sell	-500	Closed	-$25.1K	–	5826
2024 Q1	$25.1K	Buy	+500	New	+$27.1K	﹤0.01%	4864

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's MLTX Position: Q1 2026 in Review

Walleye Capital increased its MoonLake Immunotherapeutics (MLTX) stake by 323% in Q1 2026, buying an estimated $4.05M and bringing the position to 320,472 shares worth $5.97M. The position accounts for 0.02% of the portfolio, ranked #695.

Walleye Capital first reported a position in MLTX in Q3 2023 and has held it in 7 quarters since. The position peaked at $11.3M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Walleye Capital held 320,472 shares of MoonLake Immunotherapeutics worth $5.97M as of Q1 2026.
Walleye Capital bought 244,720 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $4.05M.
MoonLake Immunotherapeutics made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #695 holding.
Walleye Capital first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 7 quarters since.
Walleye Capital's MoonLake Immunotherapeutics position peaked at $11.3M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.